I'm in the Computational Methods... session on the final day of #ASHG20 The first speaker is Vincente Yepez, who will talk about "The added value of RNA sequencing over WES for variant interpretation and diagnosis of patient with rare genetic disorders"
50-75% of patients with rare diseases remain undiagnosed after WES. WGS gives all the variants, but not interpretable. VY will talk about using RNAseq to help diagnose. Focusses particularly on mitochondrial disorders #ASHG20
RNAseq can be used to resolve diagnoses in 10-15% of individuals with WES-undiagnosed mitochondrial disorders. Use a method called OUTRIDER to identify outlying gene expression signatures. Outliers are enriched for genes with rare LoF and aberrant splicing variants #ASHG20
Use FRASER to detect aberrant splicing of genes. Splicing outliers are enriched in rare splice, intronic and coding variants #ASHG20
Also examine monoallelic expression of the alternative allele. Show this is more frequent (in rare variants) on the reference allele. Combining all three methods gives an approach to obtaining a genetic diagnosis. Particularly effective in 5' and 3'UTRs #ASHG20
E.g. showed a homozygous synonymous variant that activated a splice site. E.g. 2, an intronic variant in NDUFAF5 creates a cryptic exon E.g. 3 - showed that homozyg splice acceptor variant in BUB1 did NOT result in a pathological spliced isoform #ASHG20
Finally, Margot Cousin presents on "Impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 causes a novel brain and heart developmental syndrome" #ASHG20
SHMT2 - encodes mitochondrial serine hydroxymethyltransferase 2. Key roles in amino acid metabolism and folic acid pathways, as well as mitochondrial respiration and protein translocation #ASHG20
Identified 4 individuals with biallelic SHMT2 variants. One individual has a variant disrupting a splice site. Other variants are missense on highly conserved residues, and are absent/extremely rare in gnoMAD. Variable dysmorphic features. Others incl. developmental delay #ASHG20
Next up is Helen Miranda discussing "Increased p4EBP1 underlies ALS pathology associated to P56S mutant VAPB" #ASHG20
ALS is the most common adult-onset neurodegenerative disorder. 50% of patients do not survive beyond third year of diagnosis. Pathophysiology across upper and lower motor neurones. 90% of cases are sporadic in presentation. #ASHG20
Mutations in >25 genes have been associated in ALS. Focus on VAPB. Highly conserved gene that is ubiquitously expression. P56S mutation is the causative gene for ALS type 8 - mostly identified in Brazilian population, but has been identified globally. #ASHG20
Next up is Victor Faundes, who will talk about Impaired eIF5A function causes a craniofacial-neurodevelopmental syndrome that is partially rescued in model systems by spermidine #ASHG20
EIF5A was identified as a candidate developmental disorder gene through WES. Used the DDD resource to identify a further 6 individuals with EIF5A variants, defined a novel syndrome of developmental delay and other features #ASHG20
EIF5A resolves ribosomal stalling caused by polyproline tracts. Aimed to understand how this is disrupted by the variants seen in patients. Haploinsufficiency is the most likely mechanism #ASHG20
Slightly late into the fourth plenary: David Blair discussing "Common genetic variants associated with Mendelian disease severity revealed through cryptic phenotype analysis" #ASHG20
Cryptic phenotypes are phenotypes that underlie mendelian diseases, but which are not observed. For some, this will be a liability-threshold model (mendelian as extreme of normal range), but for others it will be a phenotypic outlier model (mendelian as truly separate) #ASHG20
Need models that differentiate between the models. May be morbidity-dependent genetic modifiers - e.g. may not see effects looking at the average of the population, but may see it at the extreme percentiles of severity #ASHG20
Elise Flynn will end the session, talking about "Transcription factor regulation of genetic variant effects across tissues and individuals" #ASHG20
Genetic variants associated with gene expression = eQTL #ASHG20
eQTLs can be context specific, whether in terms of effect size or the presence/absence of an effect. Know that eQTLs are enriched in TF binding sites. Suggests that modifications to TF binding are a major mechanism by which genetic variation regulates gene expression #ASHG20
Next is Xiaolei Zhang, discussing "Annotating high-impact 5'UTR variants with the UTRannotator"
The translation of upstream open reading frames can reduce the expression of genes considerably. Can have overlapping uORF, out of frame or in frame depending on where the stop coding of the uORF lies #ASHG20
uORF perturbing variants can be disease-causing. they are under strong negative selection and appear to cause disease through LoF of genes. #ASHG20